138 - Collaborative Treatment Considerations for the Optometrist in Relapsed/Refractory Multiple Myeloma: Mitigating and Managing Ocular Adverse Events
Saturday, March 4, 2023
10:00 AM – 11:00 AM EST
Location: Georgia World Congress Center, 406/407
CE Hours: 1
AUDIENCE: OD
IN-PERSON COURSE ACCREDITATIONS: COPE 83208-SD ; IL OD
Associate Professor Emory University Atlanta, Georgia, United States
Disclosure(s): No financial relationships to disclose
Disclosure(s):
Soroosh Behshad, MD, MPH: No financial relationships to disclose
The landscape of multiple myeloma treatment is rapidly evolving, and several treatment options are available as front- and subsequent-lines of therapy. Because of the complexity of the treatment landscape and unique toxicities associated with newer BCMA-targeted treatments, education is critical to keep the multiple myeloma treatment team up to date on the most effective approaches to management to provide patients with the most appropriate course of therapy. Optometrists serve a critical role in mitigating the ocular side effects associated with the anti-BCMA agents to ensure patients receive optimal treatment for their multiple myeloma.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Relapsed/Refractory Multiple Myeloma: How has the treatment landscape changed?
Exploring novel BCMA-targeted therapies for relapsed/refractory multiple myeloma
Ocular adverse effects of anti-BCMA therapy: case-based strategies exploring their identification, mitigation, and the optometrist role
